RecruitingNCT05474430

Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity

Estimating the Risk for and Severity of Respiratory Infections Attributable to CFTR Heterozygosity


Sponsor

Philip Polgreen

Enrollment

160 participants

Start Date

Dec 20, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays. An individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactive protein, calprotectin, and lactoferrin. They will also draw a 5 ml gold top serum separator tube of blood to test fibroblast growth factor-19. The participant will answer questions from the baseline survey and report their current medications interview-style with the research team member.


Eligibility

Min Age: 18 YearsMax Age: 100 Years

Inclusion Criteria4

  • Previously tested and shown to be a CF carrier
  • English-speaking
  • Previously tested and shown to not be a CF carrier or CF patient
  • English-speaking

Exclusion Criteria3

  • Currently sick with a respiratory infection
  • Prisoner Status
  • Unable to provide own written, informed consent

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05474430


Related Trials